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Introduction
Monoclonal antibody (MAb)-directed cancer therapy has evolved in the past 3 decades into an emerging modality in clinical practice. The regulatory approvals for several of the MAb products, either in unmodified forms or as carriers of anticancer therapeutics, have created an impetus for the ongoing development of newer products and newer treatment paradigms for targeted therapy. Significant clinical impact has been documented with naked antibody products, such as rituximab (Rituxan®; Biogen Idec), trastuzumab (Herceptin®; Genentech), cetuximab (Erbitux®; ImClone), and bevacizumab (Avastin®; Genentech), used alone or in combination with other modalities. This review's focus, however, is on recent developments in MAbs used as vehicles for tumoricidal radionuclides, drugs, and protein toxins.
Different design requirements apply to the conjugation of radionuclides to MAbs on the one hand, and of drugs and toxins on the other. For radionuclides, the 'crossfire' effect of irradiation of non-targeted tumor cells means that every cell need not be targeted to be sterilized. In addition, there is no specific requirement for antibody to internalize upon binding to its antigen. Drug/toxin-conjugated MAbs have to internalize upon binding to the tumor cell surface, and release the drug/toxin in the proper intracellular compartment for efficacy. Since not all cells are targeted, there is also a perceived need to use a highly toxic drug, effective in the subnanomolar to picomolar range, for MAb-directed chemotherapy.
Radioimmunotherapy (RAIT)
The FDA approvals for two radiolabeled anti-cluster designation(CD)20 MAbs for the treatment of non-Hodgkin's lymphoma (NHL) were landmark events in the developmental history of therapy with radiolabeled MAbs [radioimmunotherapy or RAIT; ref.
(1, 2)]. Our current knowledge of the RAIT modality and its place in the management of cancer is owed to impressive strides in multidisciplinary fields of research: genetic engineering of humanized antibodies and antibody constructs, radiolabeling chemistries, availability of a multitude of therapeutic radionuclides, algorithms for internal radiation dosimetry, and innovations in treatment approaches. In this section, recent trends in radiolabeling chemistry, therapy results in hematological malignancies, and the efforts directed toward the more challenging therapy of solid tumors are outlined.
RAIT: Radionuclides & Radiochemistry
In RAIT, radionuclides with particulate emissions, linked to targeting MAbs, are used. The therapeutic effect is achieved by tissue absorption of the energies from a continuous, lowdose, irradiation from the radioactive emitters tagged to MAbs. The available choice of therapeutic radionuclides is many, and the relative merits of the various nuclides have been described (3). The radionuclide to use for specific RAIT application is a function of the target disease to be treated, radiophysical characteristics of the nuclide, its commercial availability, and the radiolabeling chemistry. Useful therapeutic radionuclides are of β-emitting, α-emitting, or Auger and conversion electron-emitting categories (Table I ). The last two categories of these generate emissions with high linear energy transfer and deposit their energies within a short distance from the nuclide's location. Typically, an α emitter has an energy deposition of ∼ 100 keV/µm compared to 0.2 keV/µm from a beta emission (4). Auger and conversion electron emitters deposit their emission energies in a highly localized manner and have practically no impact on nearest neighbors compared to emission energies from even α-emitters. These distinctions immediately point to the disease indications to which α and Auger emissions apply: single cell situations, as in micrometastatic disease, minimal residual disease, readily accessible blood borne malignancies, and locoregional application. On the other hand, β-emitters, because of their longer tissue range, can impact even non-targeted tumor populations. 131 I and 90 Y have been by far the most used of β-emitting radionuclides. 131 I is attached to MAbs via an oxidant-based direct radioiodination. For MAbs that internalize upon engaging the tumor antigen, a conventional 131 I-label on the MAbs entails a reduced tumor residence time of the radionuclide and a reduced tumor radiation dose (5). To overcome this, considerable progress has been made in the design of intracellularly-retained ('residualizing') forms of 131 I (6, 7). Even the multi-operational process associated with introducing a residualizing 131 I on MAb has been simplified recently into a '1-pot' procedure, thereby making this technology as facile as direct MAb radioiodination (8). Metallic radionuclides, such as 90 Y, need MAb-conjugated chelating agents for complexation (Figure 1 ). With 90 Y, the choice is between a group of acyclic DTPA-based chelators and the macrocyclic chelators, such as DOTA. The use of DOTA, which forms extremely stable complexes with a variety of radiometallic nuclides, lagged behind acyclic chelators, such as MX-DTPA used in the FDA-approved 90 Y-ibritumomab tiuxetan (Zevalin®; Biogen Idec), but more recent advances have made the DOTA-conjugated MAbs easy to manufacture and radiolabel with 90 Y (9). Further, 90 Y-DOTA chelate on a MAb was found significantly more stable than 90 Y-MX-DTPA chelate on the same MAb preclinically, and was predicted to deliver 52-69% less radiation dose than the DTPA chelate to the dose-limiting organ (10). These latter findings are felicitous, in as much as the in vivo stability of 90 Y-MAb is of high importance clinically; any dissociation of 90 Y from MAb is toxic to cortical bone. Other β-emitting metallic radionuclides, such as 67 Cu, 177 Lu , 186 Re, and 188 Re, have been examined to varying degrees (11-15), but none has thus far supplanted the readily available 90 Y and 131 I. Perhaps continued explorations with these radionuclides, particularly 177 Lu that combines the advantages of the chemistry of 90 Y with the radiophysical characteristics of 131 I, could prove of value. Commercial availability of the radiopharmaceutical grade of the radionulide(s) would be a prerequisite here.
The high LET emissions of α-particles (∼ 100 keV/um) have a high probability of producing DNA double-strand breaks, chromosomal damage, and cell-cycle G 2 -phase delays (4). Their short tissue range causes minimal damage to non-targeted organs. The lack of gamma emissions associated with some of these nuclides permits reduced patient isolation. The short list of α-emitters comprise 225 Ac, the generatorproduced 212 Bi and 213 Bi, and the radiohalogen, 211 At, whose availability is limited to facilities having a cyclotron. 213 Bi advantageously emits photon with a 440-keV energy, permitting determination of biodistribution and dosimetry. The decay pathway of 212 Bi produces a 2.6-meV energy γ-ray, which requires heavy shielding. For this reason, it is unclear whether this nuclide can be developed into a viable radioimmunotherapeutic. For 213 Bi nuclide, with a half-life of < 1 hr, cyclohexylbenzyl DTPA (CHX-DTPA) has been the choice as the metal chelator in view of the 'instant' labeling obtainable. A 213 Bi-labeled CHX-DTPA conjugate of anti-CD33 MAb, HuM-195, at 30 mCi/mg, resulted in a dose and specific activity-dependent cell-kill in vitro, and produced rapid targeting of tumor sites in vivo (16). 225 Ac, a 'nanogenerator' with its 10-day half-life and a cascade of decay processes to produce four α-particles, is 1000 times more potent than 213 Bi on the same MAb. For 225 Ac (t 1 / 2 = 10 ds), its DOTA chelate was found to be more stable than its DTPA-based acyclic chelates, losing just about 10% of the label in a 10-day period when incubated in serum at 37°C
. MAb labeling was performed in a 2-step process of labeling 225 Ac with DOTA-NCS, followed by conjugation to MAb (17) . In a significant fraction of the animals bearing human prostate carcinoma or systemic human lymphoma, single nanocurie levels of 225 Ac-MAbs induced tumor regressions and prolonged survival, and the treatment itself was well tolerated (18). 211 At is introduced on to MAb by a 2-step procedure of synthesizing N-succinimidyl 3-[ 211 At]astatobenzoate followed by MAb conjugation (19). 211 At-anti-tenascin MAb 81C6, at 4-18 µCi intrathecal doses, produced significant increase in median survival rate in a preclinical model of neoplastic meningitis (19).
Auger emissions and conversion electron emissions mostly have emission energies of < 100 keV deposited in a very localized manner, and this has been shown to be useful for sterilizing micrometastases in experimental tumor models. Both a rapidly internalizing anti-CD74 MAb, LL1 (20), and a non-internalizing anti-CD20 MAb, 1F5, gave efficacious therapies in preclinical lymphoma xenograft models in SCID mice, using 111 In, 67 Ga, and 125 I labels (21, 22) . Since the Auger emitter deposits its energy only to the cells bound by the MAb, non-specific or 'cross-fire' effects are minimal, making the use of this type of radionuclide safe. In two phase I/II clinical trials using 125 I-anti-EGFR MAb in glioma patients (23) or 125 I-A33 MAb in colon cancer patients (24), a dose as high as 500 mCi could be administered without reaching the MTD. The potential of Auger and conversion electron emitters has been addressed (25), and any definitive role for these in clinical RAIT must await more experimentation with more promising radionuclides, such as 111 In and 67 Ga (22) .
RAIT in Non-Hodgkin's Lymphoma
There are now two approved RAIT products for NHL, both targeting the CD20 antigen expressed by malignant and normal B lymphocytes. 90 Y-ibritumomab tiuxetan is a 90 Ylabeled conjugate of a murine MAb and MX-DTPA, and 131 I-tositumomab (Bexxar®; GlaxoSmithKline) is a directly-radioiodinated murine MAb. These products are approved for the treatment of chemotherapy-and/or rituximab-refractive patients with low-grade (follicular) and transformed NHL, with < 25% involvement of the disease in bone marrow [reviewed in: (26, 27) ]. As part of the treatment regimen, unlabeled MAbs -chimeric MAb rituximab for 90 Y-ibritumomab tiuxetan and murine MAb tositumomab for 131 I-tositumomab -are used in conjunction with the murine radiolabeled MAbs. This pretreatment is to deplete peripheral B cells and reduce splenic uptake and thereby improve biodistribution of the subsequently administered radioantibody. An imaging dose of the 131 I-tosiumomab is given initially to customize the subsequent therapeutic 131 IMAb dose to individual patients. With 90 Y-ibritumomab tiuxetan, a diagnostic dose of 111 In-ibritumomab tiuxetan is first given to determine the pharmakokinetics of the labeled antibody prior to the administration of the therapeutic dose of the 90 Y-labeled antibody. Head-to-head clinical trials comparing radiolabeled MAb with the unlabeled MAb, with respect to both RAIT products, confirmed the importance of radioactivity in terms of significantly improved therapeutic effects. Hematopoietic toxicity is the dose-limiting toxicity in these treatments. Severe drops in platelet and white blood cell counts were common, but manageable with blood transfusions and colony-stimulating factors. Toxicity was more severe in patients with more severe prior treatments.
The nonmyeloablative MTD of 90 Y-ibritumomab tiuxetan is 0.4 mCi/kg; in low-grade lymphoma patients (n = 34), an overall response rate (ORR) of 82% and a complete response rate (CR) of 26% were recorded (28). Time to disease progression and median duration of response (MDR) in responders were 12.9 + mo and 11.7 + mo, respectively. In a randomized clinical trial in relapsed or refractory low-grade lymphoma patients (n = 73), an 80% ORR and 30% CR were observed compared to 56% ORR and 16% CR in patients treated with rituximab alone [n = 70; ref. (29) ]. In rituximab-refractory patients, a 74% ORR and a 15% CR rate were found (30).
131 I-tositumomab was evaluated in > 1000 patients to date (27). In chemotherapy-treated or rituximab-refractive patients with low-grade NHL, > 65% objective response rate, > 20% CRs, and high duration of response were obtained (31, 32) . The clinical trials undertaken to expand the scope of 131 I-tositumomab produced impressive results. In 76 previously untreated patients with stage III or IV lowgrade lymphoma, 131 I-tositumomab as a front-line therapy produced 95% objective response and 75% CR, with a median progression-free survival of 6.1 years (33). In a phase II trial in 90 previously untreated patients with advanced follicular lymphoma, combination therapy involving CHOP chemotherapy resulted in 90% ORR and 67% CR (34).
Myeloablative regimen with stem-cell transplantation produced high response rate and duration of response, with survival rate better in contrast to that with high dose chemotherapy with stem-cell rescue (35). Finally, in a small randomized trial comparing tositumomab with tositumomab plus 131 I-tositumomab, ORRs and CR rates of 55% and 33%, repectively, for the latter, versus 17% and 8%, respectively, for the MAb-alone group were reported (36).
Other promising radiolabeled MAbs are at various stages of clinical trials. These include 90 Y-epratuzumab and 186 Reepratuzumab (Immunomedics, Inc.) , which are radiolabeled versions of a humanized anti-CD22 MAb, hLL2 (37-40); radiolabeled versions of Lym-1 (Oncolym; Peregrine Pharmaceuticals), which is a murine MAb directed to HLA-DR10 β-subunit expressed on most malignant B-cells (12, 13, 41) ; and 131 I-labeled rituximab (42).
RAIT in NHL is also being examined using 'pretargeting' approaches. 'Pretargeting' is discussed in more detail in a later section. In a 3-step pretargeting format, unlabeled rituximabstreptavidin conjugate was first administered to patients with low grade NHL; this was followed by administrations of a clearing agent, to remove circulating conjugate, and finally 30-50 mCi/m 2 of 90 Y-DOTA-biotin. In this trial in which seven patients received the radiolabeled biotin, a median tumor-towhole body dose ratio of 38:1, and three CRs and one PR were reported (43). Immunogenicity to streptavidin developed in a majority of patients. The potential of pretargeted RAIT was again demonstrated recently using a 2-step bispecific MAb (bsAb) approach in a preclinical model of NHL. In this, tumor targeting was first achieved with an unlabeled humanized anti-CD20 × anti-HSG bsAb; this was followed by the subsequent administration of a 90 Y-peptide containing the histamine-succinyl-glycine (HSG) motif that latches on to its recognition site on the bsAb. Antitumor response was reported to be superior to treatment using the directly labeled 90 Y-anti-CD20 humanized MAb, hA20 [P<0.007; ref. (44)].
Data from clinical RAIT trials in NHL demonstrate that even low tumor doses produce therapeutic response, that human anti-mouse antibody reaction due to a murine MAb is generally low, and that pretargeting is a promising approach worthy of continued exploration. Although regulatory stipulations permit RAIT application in only chemotherapy or immunotherapy refractory patients, evidence of its superior efficacy in a front-line therapy trial in patients with NHL (33) underscores a need for a paradigm shift in how the RAIT modality is applied clinically.
RAIT in Other Hematological Cancers
Adult T-cell leukemia (ATL) is an aggressive form of leukemia. High-affinity IL-2 receptors are expressed by ATL cells, and can be targeted by anti-Tac MAb. A murine 90 Y-anti-Tac MAb was used in a dose escalation trial and subsequently in a phase II trial in ATL in which patients uniformly received 10 mCi of the agent. An ORR of 56% (2 CRs and 7 PRs) was observed in 16 evaluable patients (45). An anti-CD5 antibody, T101, radiolabeled with 90 Y, was studied in 10 patients with chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL); two PRs in the CLL category; and three PRs in the CTCL category were reported (46). CD33 antigen expression on myeloid precursor cells and myeloid leukemia cells provides an opportunity for the application of RAIT. Logically, this was exploited by targeting radiolabeled anti-CD33 MAbs, M195, and humanized M195 (HuM195), in acute myeloid leukemia (AML) patients. 131 I-M195, as a combination therapy with autologous bone marrow transplantation (ABMT) regimen, was observed to produce a high CR rate (47), and 213 Bi-HuM195 was subsequently examined in a dose escalation study in AML. In this 18-patient trial, a target-to-whole body ratio 1000-fold greater than that obtained with 131 I or 90 Y RAIT was achieved, and 14 of 18 patients had a decreased percentage of bone marrow leukemia blasts after therapy (48). A phase I/II trial in small-volume disease of AML, using 4 dose levels in the range of 0.5-1.25 mCi/kg of 213 Bi-HuM195, indicated that 213 Bi-HuM195 could lead to CRs (49). Table II details clinical data for prominent RAIT products for NHL, either approved or in advanced clinical trials. The table also contains data for adult T-cell leukemia, chronic lymphocytic leukemia, and cutaneous T-cell lymphoma.
RAIT in Solid Tumors
In contrast to striking clinical responses seen with radiosensitive hematological tumors, solid tumors have been less responsive to RAIT. There are a number of reasons for this. An achievable accretion of < 0.01% of injected radioactivity of radiolabeled MAb per gram of tumor corresponds to a calculated delivered cumulative tumor dose of < 15 Gray (Gy), while a radiation dose of ≥ 50 Gy is considered necessary for a therapeutic response in solid tumors. The injectable radioactivity itself is limited by the amount that will produce no more than 3 Gy of radiation dose to bone marrow. Further, solid tumors are relatively radioresistant unlike hematologic tumors whose radiosensitivity is in part due to the ease with which lymphoid cells undergo apoptosis at relatively low absorbed radiation doses. In addition, RAIT is often evaluated in patients with large tumor burden, limited bone marrow reserve, poor performance status, and short life expectancy.
Several approaches have been undertaken to improve solid tumor therapy: (i) pretargeting to achieve greater therapeutic index; (ii) locoregional administration; (iii) application to minimal residual disease and in adjuvant settings; and (iv) increasing radiosensitivity of the tumors with drugs.
Pretargeting
This procedure separates tumor targeting of the MAb from that of the radionuclide, and results in a reduced systemic toxicity due to a circulating radionuclide. Although many formats are possible, the two most investigated pertain to (i) streptavidin (avidin)-biotin as components of pretargeting (50, 51) and (ii) bispecific antibody (bsAb) approach in which the components are a bsAb, with specificities for tumor antigen as well as a hapten, and a peptide bearing the hapten (51, 52). The first format requires a 'clearing step' to remove circulating MAb prior to administration of radiolabeled hapten, while a clearing agent is not needed in the bsAb approach. These two formats were exemplified in the section on NHL. While pretargeting is procedurally more complex than using radioantibody, available evidence suggests that this protocol can deliver a radiation dose to tumor equal to or better than a directly radiolabeled MAb, but with much reduced marrow toxicity. For example, using an 'affinity-enhancement-system ('AES')' form of the simpler bsAb-based pretargeting, radiation doses of 2.9-184 cGy/mCi to tumor were delivered in 26 medullary thyroid cancer patients who received 40-100 mCi of radioactivity of the 2 nd step hapten reagent. In this trial (53), 20-50 mg of the bsAb, consisting of Fab' fragments of anti-CEA and anti-DTPA-indium MAbs, was administered, followed by targeting with the radiolabeled hapten consisting of a peptide with two In-DTPA moieties as well as [ 131 I] iodotyrosine. Such high achievable tumor doses, combined with high administered radioactivity, produce high total tumor radiation doses, which distinguishes pretargeting from the direct radioantibody approach. In a phase II trial in patients with metastatic colorectal cancer, a NR-Lu-10/streptavidin conjugate was pretargeted, followed by clearing agent, and finally 110 mCi/m 2 of 90 Y-DOTA-biotin; an ORR of 8% was recorded, with the estimated dose to the tumor in responders being 4,000-6,000 cGy (54). However, the targeting nature of NR-Lu-10 MAb produced high GI toxicity. A different version of avidin (sAv)/biotin-based pretargeting was followed in a phase I/II trial of high-grade glioma. In this latter approach, biotinylated anti-tenascin MAb, BC4, was administered in the first step, followed by avidin/sAv, and, finally, 60-80 mCi/m 2 of 90 Y-DOTAbiotin. In this 48-patient study, in which some patients received two additional cycles of therapy, a 25% objective response rate, a 52% disease stabilization rate, and > 1 yr of duration of response in some patients were observed (55). In an adjuvant setting after surgery and radiotherapy, the median disease-free survival of 28 mo in glioblastoma patients (n = 19) and 56 mo in grade III glioma patients (n = 17) were significantly longer than in patients who did not receive pretargeted RAIT adjuvantly (56).
Locoregional Application
Treatment of brain tumor by injection of radioantibody via a catheter inserted in the cavity after debulking surgery provides one of the best examples of RAIT application. In a phase II study in 27 patients with glioblastoma multiforme (GBM), locoregional treatment with 131 I-labeled 81C6 antitenascin MAb (the MTD was 100 mCi, with the dose-limiting toxicity being neurologic) resulted in a median survival of 79 wk; and in a subgroup of patients > 50 y of age, the median survival was 65 wk compared to 39 wk for historical controls who received chemotherapy and radiotherapy (57). In a phase I adjuvant clinical trial using 2-10 mCi of chimeric 211 At-81C6 (10 mg MAb) administered in the cavity after surgical resection of tumor in 11 malignant glioma patients and one anaplastic oligodendroglioma patient, very favorable radiation dosimetry was found: the radiation dose at the interface was 743 Gy at the 2 mCi dose, compared with 0.017-0.02 Gy for normal brain, bone marrow, liver, and spleen. No dose-limiting toxicity was observed. The survival rate was stated to be encouraging (58). In small-volume disease of malignant glioma in patients (n = 105), locoregional RAIT with 131 Ilabeled anti-tenascin MAbs BC-2 and BC-4, administered via a catheter, resulted in a 51.6% ORR and a significantly improved median survival (59).
Minimal-disease/Adjuvant RAIT
The advantage of this approach, illustrated with examples in Locoregional Application and Pretargeting sections, is further addressed here. An interesting example is provided in the report of RAIT in colorectal patients after resection of liver metastases. In this phase II study, the > 5 year-survival rate for patients receiving 50-60 mCi/m 2 administered dose of 131 I-hMN-14 ( 131 I-anti-CEA MAb; 131 I-labetuzumab) was 50% compared to 8% for the control group without post resection RAIT (60). It was previously shown that favorable conditions existed for the systemic delivery of high tumor doses, > 100 cGy/mCi, by 131 I-labeled anti-CEA MAbs, in small lesions of colorectal and medullary thyroid cancers (61). Long-term survival of patients with advanced ovarian cancer, who had undergone complete remission with surgery and chemotherapy, was examined after administration of intraperitoneal RAIT with 18 mCi/m 2 of 90 Ylabeled MAb, HMFG1. In this cohort, median survival was not reached at 12 years, and survival rate was > 78% at 10 years versus 32% for the control group without adjuvant RAIT [P = 0.003; ref. (62,63) ].
Combination of RAIT with Chemotherapy
The rationale for combining chemotherapy with RAIT is that drugs could act as radiosensitizers, and with optimization of temporal administrations of the two agents, radiolabeled MAb can have an advantageous impact at the cell cycle phase when the cells are radiosensitive. Several reports have documented the synergistic drug-RAIT combinations in preclinical models of cancer (64-67), and also addressed the scope of such combinations (68-70).
MAb-drug Conjugates
Systemic cancer chemotherapy targets rapidly proliferating tumor cells, but the inherent lack of specificity leads to normal organ toxicity such as GI tract and bone marrow toxicity. The advent of hybridoma technology has spawned an era of active exploration in the MAb-directed delivery of chemotherapeutic drugs to the disease sites with considerable potential for efficacious and less systemically-toxic chemotherapy.
Several factors impact the effectiveness of a MAb-drug conjugate, such as (i) the preservation of the MAb's immunoreactivity and avidity after conjugation to the drug, (ii) the stable linking of the drug to the MAb, (iii) internalization of the MAb-drug conjugate upon binding to the target antigen on the tumor cell surface, and (iv) the intact release of the drug intracellularly. Because the 'cross-fire' effect of radiation associated with RAIT is absent, each tumor cell needs to be targeted by MAb-drug conjugate for therapy. MAb accretion is < 0.01% of the injected dose in humans, and only a small fraction of the tumor population is targeted. In addition, there is the presence of antigen-negative tumor cells. All untargeted tumor populations can be impacted by the diffusion of the intact drugs from the tumor cells that are targeted by the MAb-drug conjugate. To have such an impact, it is believed that the drugs used in MAb-drug conjugate design must be highly cytotoxic and effective in nanomolar to picomolar range. These and other issues of targeted chemotherapy have been reviewed (71).
Early work on protein-drug conjugates indicated that a drug needed to be released in its original form after internalization (72). Another decade would pass before this concept took hold in the area of MAb-drug conjugate design. Internalization by endocytosis results in routing of the conjugate to endosomes and lysosomes, where MAb catabolism takes place. The degradation of MAb by lysosomal enzymes occurs to the level of amino acids, as has been convincingly demonstrated in experiments with radiolabeled antibodies (5). The question then becomes one of the fate of the attached drug, whether it is liberated intact or as a conjugate of an amino acid. For instance, it is known that an amide bonding of the chelating agent DTPA to the ε-amino group on the lysine is not processed after internalization of the MAb-DTPA conjugate, but remains as lysine-attached DTPA (73). Thus, the direct amide bonding of a drug molecule to the lysine side chain on an MAb will result in the liberation of a lysine derivative of the drug, not the intact drug, in the lysosome; the lysine conjugate of the drug may be much less active than the intact drug, if at all. Therefore, a cleavable bond between MAb and the point of attachment to the drug becomes important. The cleavage of a suitably placed linker between the MAb and the drug is then triggered by the unique lysosomal environment as follows: (i) The relatively low pH of 5 in lysosomes can cleave pH-sensitive groups such as hydrazone; (ii) high concentration of glutathione results in the cleavage of disulfide bonds between drug and MAb; and (iii) specific peptide sequences, placed between the drug and MAb, are cleaved by certain peptidases found almost exclusively in lysosomes.
The following sections describe conjugates that incorporate the three types of cleavable linkers specified above. Structures of the bifunctional derivatives of the drugs used in the MAb-drug conjugates discussed herein are given in Figure 2 . Preclinical therapeutic efficacy has been documented with these conjugates, some of which are in clinical trials and one product is already approved by the FDA.
MAb-drug Conjugates: pH-sensitive Linkers

BR96-doxorubicin Conjugate
The hydrazone of doxorubicin (Dox) with a maleimido hydrazide was examined as a conjugate of anti-Lewis-Y MAb, cBR96, which is expressed on many solid tumors. The conjugate was prepared by a maleimide-thiol reaction using disulfide-reduced MAb, thereby generating a conjugate possessing 8 Dox molecules (74). Dox belongs to the group of anthracycline antibiotics, and its 50% inhibitory concentration (IC 50 ) against many cell lines is in the submicromolar level. cBR96-Dox was found to give impressive regressions and cures of established breast, lung, and colon human tumor xenografts in athymic mice, and also brought about a 70% cure rate in a systemic lung tumor model (75). The doses required to achieve these results were high, of the order of 2-14 mg of the conjugate (50-400 µg of Dox equivalent) in a 20 g mouse. The report of this preclinical efficacy, the first of its kind, was a significant achievement in targeted therapy with MAb-drug conjugates. However, phase I and phase II clinical trials in breast cancer patients, using BR96-Dox conjugate at a dosing schedule of 700 mg/m 2 , failed to show clinically significant benefit; GI toxicities were observed in all patients (76). Normal tissue cross-reactivity of the antibody, due to the presence of the antigen in the GI tract, could have contributed to the observed toxicity.
The conjugate cBR96-Dox, renamed SGN-15, is now being examined in synergistic combination with docetaxel (77). The combination requires using less of the conjugate, thereby reducing GI toxicity. In a randomized Phase II study in patients with advanced or metastatic non-small cell lung cancer, patients received either 200-350 mg/m 2 of SGN-15 plus 35 mg/m 2 of docetaxel (Doc) or Doc alone. Median overall survival and probability of survival at 1 year were 7.3 mo. and 35%, respectively, for the combination regimen compared to 5.9 mo. and 21%, respectively, for the Doc alone group.
Calicheamicin Conjugates
The FDA approval of gemtuzumab ozogamicin (Mylotarg®; Wyeth), a MAb-drug conjugate, for acute myeloid leukemia was a milestone in targeted cancer chemotherapy (78). This product is an anti-CD33 MAb (humanized P67.6 MAb) conjugate of a calicheamicin hydrazide derivative, N-acetyl gamma calicheamicin dimethyl hydrazide, linked with a "AcBut" linker to the lysines of the MAb at an average substitution ratio of 2-3 drugs/MAb (79). Calicheamicin is a highly cytotoxic drug that binds to DNA minor groove, resulting in DNA double-strand breaks. The drug conjugate is active in vitro against CD33+ cells at 0.04 ng/mL drug equivalent concentration. The hydrozone bond of the bifunctional drug is hydrolysed to the extent of 6% at pH 7.4 and 97% at pH 4.5 upon incubation at 37 °C for 24 h. In therapy experiment in athymic mice bearing 200 mm 3 HL-60 xenografts s.c., complete tumor regression was noted by day 100 in animals (n = 5) treated with 3 doses of 18 mg/kg of the MAb-calicheamicin conjugate, which was near the MTD of 300-400 µg/kg of drug equivalent (79). The linker chemistry used in this conjugate contains two cleavable bonds, namely a hydrazone and a disulfide. In a phase II single-agent clinical trial in for treatment of CD33 positive acute myeloid leukemia patients in first relapse, 30% remissions and a median 6.8 months relapse-free survival were recorded, and a 1-year survival probability for all treated patients was 31% (80).
The same bifunctional calicheamicin as in gemtuzumab ozogamicin was more
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Figure 2: Bifunctional derivatives of drugs currently used in the preparation of antibody-drug conjugates: (a) Calicheamicin derivative (top); methyldithio-maytansinoid, DM1 (bottom). For MAb conjugation with DM1, the following sequence was used: DM1 was reduced with dithiothreitol; MAb was derivatized with N-succinimidyl-3-methyl-3-(2-pyridyldithio) propionate; and reduced DM1 was reacted by disulfideexchange with derivatized MAb. (b) doxorubicin hydrazone (top); bifunctional MMAE (bottom).
a b
recently conjugated to a humanized anti CD22 MAb, G5/44, and the conjugate was shown to be efficacious in systemic lymphoma in male SCID mice (81). The tumor initiation was done by injecting i.v. 1 × 10 7 Ramos cells, and the treatment was initiated by i.p administration of various doses, ranging from 10 µg-160 µg/kg given three times, at 3, 9, 15, or 21 days post tumor initiation. The lowest non-lethal dose tested was 80 µg/kg, and cure rates of 80-100% were found out to 100 days with doses of 10, 40, and 80 µg/kg, each given three times. Thus, the treatment was effective against minimal, established, and advanced disease. The 160 µg/kg dose caused treatment-related mortality in 50% of the animals.
In a later variant of the bifunctional calicheamicin, the hydrazone part was omitted, and the linking was done via amide bonds to lysines of an anti-MUC1 MAb, CTM01 (82). The conjugate was as good or better than the one lacking the hydrazone bond, and was also potent against resistant cell lines (83).
Influence of the Carrier MAb on Curative Therapy Using a Moderately Cytotoxic Drug
That the nature of the antibody in the MAb-drug conjugates could play a significant role in effecting specific and durable tumor regressions was shown preclinically by the use of an anti-CD74 MAb, LL1 (Immunomedics, Inc.), as the carrier of moderately cytotoxic doxorubicin (Dox). (85)]. All ten animals were cured when the same dose was administered at an advanced stage of the disease 10 days after tumor initiation, and significant survival was recorded (P<0.005 vs. untreated) even when administered 14 days after tumor initiation when the animals were close to paralysis (Figure 3) . A 90% survival rate was observed (n = 10) at 182 days when a single 117 µg dose of LL1-Dox (3 µg of Dox equiv.) was injected 5 days after tumor initiation, and significant therapeutic effect (P<0.001) versus untreated control was also noted with a single 39 µg dose. The maximum dose of 350 µg of LL1-DOX was not the MTD, but merely the protein dose considered to be antigen-saturating. The curative therapy with LL1-Dox was antibody-specific, and a similar therapeutic efficacy was also demonstrated using the humanized LL1-Dox (hLL1-Dox) conjugate. The MTD of free Dox in mice is 354 µg, which is about 100-fold more than the Dox equivalent in the 117 µg dose of the conjugate. This point is significant in comparison to doses very near MTDs employed in preclinical therapies using other MAb-drug conjugates.
Impressive preclinical therapy using hLL1-Dox was also demonstrated in a systemic model of human multiple myeloma in SCID mice (86). An i.v. dose as low as 50 µg of hLL1-Dox (1.5 µg Dox equivalent), administered 5 days after tumor initiation with 1 × 10 7 MC/CAR cells, led to 90% survival rate (n = 10) at 200 days, while a dose of 125 µg or higher resulted in a 100% survival rate. No evidence of treatmentrelated toxicity to any major organs was seen by histopathological analysis, even at the highest dose of 2.5 mg of MAbdrug conjugate (70 µg of Dox equiv. per mouse) tested.
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MAb-drug Conjugates: Disulfide Linkers
Disulfide-cleavage by intracellular glutathione represents another approach that has been successfully applied as a proprietary platform technology in the design of a number of conjugates of internalizing humanized antibodies with highly cytotoxic drugs (71). The conjugates contain a hindered disulfide, rendering them relatively stable while in circulation, but cleaved by the reductive environment in lysosomes. The lead product in this class is cantuzumab mertansine, which consists of a humanized MAb, huC242, specific for CanAg antigen (a form of MUC-1) widely expressed on the surface of carcinomas, linked to a highly cytotoxic antimicrotubule agent DM1, which is a derivative of the natural product maytansine. DM1 has IC 50 value in the picomolar range. The lysine groups of MAb are derivatized to contain a thiopyridyl disulfide moiety, which are then reacted with activated thiol groups on DM1, to generate conjugates with 3-4 drugs per MAb molecule. In a preclinical study using the conjugate of the murine MAb, eradication of large s.c. human colon tumor xenografts in SCID mice were documented (87). In a phase I trial in patients with CanAgexpressing malignancies and refractory to standard therapy, a dose escalation in the range of 22 mg-295 mg/m 2 was carried out in 37 patients, 32 of whom had colorectal cancer (88). The recommended dose was established at 235 mg/m 2 every three weeks, for a median number of two courses per patient. The study showed tolerance to treatment, evidence of tumor localization, and minor responses and disease stabilization. A certain level of cleavage of the drug from the conjugate in plasma resulted in an increased level of native antibody over time. Reversible acute transient hepatic toxicity was associated with the treatment. Gemtuzumab ozogamicin, as described above, also contains a disulfide bond in addition to the acid-sensitive hydrazone bond. In a later variant, the bifunctional calicheamicin was designed to contain only the disulfide bond.
MAb-drug Conjugates: Cathepsin B-cleavable Peptide Linkers
Yet another approach is based on incorporating a cathepsin-B-cleavable bond between the MAb and the drug. The rationale for this is that cathepsin B is a lysosomal cysteine peptidase, not expressed extracellularly, and therefore the cleavable bond would be stable in circulation and readily cleaved in the lysosomal compartment. Examples of specific peptide sequences that are cleavable are Ala-Leu-Ala-Leu, Gly-Phe-Leu-Gly, Phe-Lys, and Val-Cit (72, 89).
In the preparation of a BR96 conjugate of doxorubicin using this method, an additional 'self-immolative' spacer between Dox and C-terminus of the dipeptides Phe-Lys and Val-Cit was found necessary (89). This immolative spacer, 4-aminobenzyl alcohol in the form of anilide, undergoes a spontaneous [1,6]-fragmentation after intracellular cleavage of the anilide bond. The conjugate was prepared by reacting a maleimide group on the bifunctional drug with thiol groups on the MAb generated by reducing interchain disulfide bonds. The drug/MAb substitution ratios of 8 and 4.4 for conjugates with Phe-Lys and Val-Cit spacers, respectively, were reported. Drug release half-lives of 1h-4h were noted for conjugates incubated with cathepsin B or rat liver lysosomes, with no observable release in human plasma. The conjugates exhibited antigen-specific cytotoxicities against human lung carcinoma (L2987) and colon cancer (HCT116) cell lines. A similar approach was reported for the preparation of a BR96-camptothecin conjugate (90).
More recently, monomethyl auristatin E (MMAE), structurally related to the antimitotic marine natural product dolastatin 10, with IC 50 values in the nanomolar range against several carcinoma and lymphoma cell lines, was examined for MAb-drug conjugate preparations (91, 92). MMAE was modified to possess the cathepsin B-cleavable Val-Cit dipeptide linker and a maleimide for MAb conjugation. The MMAE conjugate of the anti-CD30 MAb cA20, with specificity for anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD), was evaluated (92). This conjugate displayed specific cytotoxicity against CD30 + Karpus 299 ALCL cells in vitro. In a s.c. model of ALCL in SCID mice, with a starting mean tumor volume of 100 mm 3 , therapy was started at a 1 mg/kg dose of the conjugate (containing 5% of the MTD of free drug) given intravenously every 4 th day for four injections. MAb-specific complete tumor regression was seen in five of five mice out to 95 days, while untreated mice were sacrificed within 25-30 days due to progressive disease. In a systemic model of the same disease using the same dosing schedule, four out of five mice survived for the duration of 130 days of the study, when the treatment was started on day 5 or day 9 after tumor initiation. Untreated animals were sacrificed by day 40. In a s.c. model of HD, generated using L540cy tumor cells, the therapeutic efficacy was significant, but less pronounced than in the ALCL model; partial regressions were observed in all the animals given the 1 mg/kg dosage of the conjugate.
MAb-drug Conjugates: Which Cleavable Linker to Use?
Ideally, the 'cleavable linker' has to be stable in circulation in vivo and be cleaved only upon binding to tumor antigen and subsequent internalization. The in vivo stabilities of different types of linkers have been inferred from comparisons of the circulation half-lives of MAbs with that of the respective drug conjugates (93). In mice, the half-life of a cAC10 MAb is stated to be 14 days, whereas that of a conjugate possessing a dipeptide liker is 6 days; cBR96 MAb has a circu-lating half-life of 12.5 days compared to a half-life of 1.8 days for cBR96-doxorubicin conjugate possessing an acidcleavable hydrazone bond; humanized C242 MAb and the corresponding disulfide-linked conjugate of a maytansine derivative have half-lives of 4.2 days and 1 day, respectively. These data show that in fact there is no ideal linker in terms of total inertness, nor is it clear if that criterion indeed needs to be met in the MAb-drug design. Perhaps the question of linker stability is better viewed in the context of the therapeutic indices obtainable using particular combinations of the MAb, the drug, and the linker.
With regard to enzyme-cleavable linkers, intracellular enzymes other than cathepsin B should be also considered. For example, cathepsin E, an aspartic proteinase, has been implicated in the antigen processing within the class II major MHC pathway (94, 95) . Cathepsin E may thus play a significant role in the catabolism, in lymphoid cells, of MAbs that target class II MHC antigen, and thereby provide a basis for the design of MAb-drug conjugates with a cathepsin E-cleavable linker.
The stability requirement under physiological condition may appear to be particularly stringent with conjugates of supertoxic drugs, such as maytansine or calicheamicin. This is because, unlike conventional chemotherapeutics, such as doxorubicin, that have known toxicity profiles, supertoxic drugs were rarely or never tested systemically in patients due to their low therapeutic index, and any leakage of these from the corresponding MAb conjugates can pose unacceptable normal organ toxicities. In these instances, the enzymecleavable peptide linker, and perhaps a stabilized disulfide linker, would appear to be useful. A hydrazone linker has an advantage over a peptide linker in that the drug release is relatively fast in lysosomes, the preparation of a relevant bifunctional variant of the drug for MAb conjugation can be less complex, the linker is less hydrophobic, and potential variability in intratumoral protease expressions is not an issue. These are not insignificant factors in the clinical development of a useful MAb-drug conjugate that can be manufactured on a commercial-scale. Thus, the pH-sensitive hydrazone linker would be indicated if the MAb conjugate of a systemically used chemotherapeutic can be shown to be efficacious, preferably at a fraction of the tolerated dose of free drug.
MAb-toxin Conjugates
Targeting tumors with antibody conjugates of highly potent protein toxins, referred to as immunotoxins, represents an important approach to cancer therapy (96-100 
Preparation of MAb-toxin Conjugates
There are principally two general methods of producing these conjugates. The first method is the conventional chemical conjugation, whereby the antibody and the toxin molecules are coupled by a disulfide bond (102, 103). The second method involves recombinant DNA techniques (100). The ability for the toxin to separate from the conjugate and enter the cytosol is a key requirement for toxin action.
With chemical conjugates, the reduction of the disulfide bond by intracellular glutathione liberates the toxin from the conjugate. Generally, antibody conjugates of plant toxins have been prepared in this way. The nature of the disulfide bond in the chemical conjugates has been a subject of numerous studies. It is now accepted that the disulfide linker must be sterically hindered so as to avert premature cleavage in the circulation. Sterically hindered disulfides have been introduced containing one methyl adjacent to the sulfur, or gem-dimethyl groups adjacent to sulfur, or methyl groups adjacent to each sulfur atom of the disulfide bond (102, 103).
The second method involves fusion of genes encoding an antibody and the catalytic domain of a toxin, followed by expression of the MAb-toxin fusion protein in bacterial or mammalian host systems. Conjugates of bacterial toxins prepared by recombinant DNA methods are said to possess the ability of the catalytic domain of the toxin to separate from the fused antibody. As described further below, the fusion proteins of antibodies and ranpirnase (an RNase) also display potent tumoricidal activity, indicating that the requisite RNase presentation was achieved intracellularly.
Conjugates of Plant Toxins
In this category, extensive work has been done with ricin, with antibody conjugates prepared using blocked ricin, or ricin A-chain, or deglycosylated ricin A-chain (dgA). A number of early phase I clinical trials in lymphomas showed PRs or CRs in the 12-75% range in patients with bulky tumors, but the responses were modest in solid cancers (96). A disulfide-linked conjugate of the anti-CD25 MAb, RFT5, and dgA, was evaluated in a phase-I trial in heavily pretreated patients with refractory Hodgkin's lymphoma; an MTD of 15 mg/m 2 was delineated and clinical responses of three PRs, one minor response, and three SD were observed among 15 patients treated (104).
Antibody conjugates of gelonin also have been extensively investigated. In a preclinical intraperitoneal model of myeloid leukemia, a recombinant gelonin conjugated to an anti-CD33 MAb, Hum195, produced a significant response: 50% of treated animals did not develop tumor for 5 months and the rest showed significantly retarded tumor growth, when the agent was administered 10 days post-tumor implantation (105). A MAb-gelonin conjugate, targeted to nude mice bearing A375 human melanoma tumor xenografts, produced tumor suppression and a 213% increase in mean survival time compared to untreated controls (106).
Conjugates of Bacterial Toxins
Pseudomonas exotoxin (PE) was modified to a bindingdomain-deleted protein, PE40, and the latter, with additional modifications, was conjugated to the anti-CD22 MAb, LL2, or its Fab' fragment. These conjugates led to specific and complete regressions of s.c. NHL tumors in nude mice, when given intraperitoneally 1 day later (107). A 63-kDa recombinant immunotoxin, BL22, was designed combining a domain-deleted PE, PE38, with the dsFv fragment of the anti-CD22 MAb, RFB4. The use of disulfide-containing dsFv fragment preserved the binding affinity of the MAb, while in the scFv version of the conjugate, a 3-fold loss of MAb affinity was found. A dose of 5 µg/animal in the same lymphoma animal model in nude mice as described for the LL2 conjugates cured 50% of the animals. In a phase I clinical trial in patients with various B-cell malignancies, the immunotoxin treatment was well tolerated. In this doseescalation study, 0.2-4 mg was administered as a 30-min infusion every other day for a total of three infusions (108). Chemotherapy-resistant patients with hairy cell leukemia responded the best, with 11 CRs and two PRs out of 16 treated. Retreatment of three relapsed complete responders, after a median follow-up of 16 months, resulted in a second CR.
A recombinant immunotoxin comprising interleukin-2 and a domain-deleted version of diphtheria toxin, denileukin diftitox (Ontak®; Ligand Pharmaceuticals), has been approved for the treatment of cutaneous T-cell lymphoma.
RNase Conjugates
The amphibian RNase, ranpirnase (Onconase®; Alfacell), abbreviated as rap, is a 11.8-kDa protein belonging to pancreatic RNAse superfamily. It has an advantage over plant and bacterial toxins in terms of its lack of immunogenicity. It is the only RNase that has been tested for its anticancer activity in patients, and in this respect also differs from other toxins that can only be used as conjugates of tumor-targeting carriers (109). Interestingly, ranpirnase has been shown to be orders of magnitude more potent when used as a MAb conjugate. The first preparation and evaluation of the chemically constructed conjugate of an anti-CD22 MAb, LL2, and ranpirnase was reported (110). LL2-ranpirnase chemical conjugate increased the in vitro potency of ranpirnase 10,000-fold against Daudi Burkitt lymphoma cells; and significantly improved the survival of animals bearing advanced disseminated lymphoma, in comparison to untreated animals, while reducing systemic toxicity of the toxin. More recently, the design and evaluation of a recombinant immunotoxin comprising two ranpirnase molecules fused to the light chains of the IgG4 form of the anti-CD74 humanized MAb, hLL1, was reported (111). The fully-characterized hLL1-ranpirnase fusion protein displayed significant and specific cytotoxicity to Daudi lymphoma and MC/CAR multiple-myeloma cell lines in vitro. In a systemic lymphoma in SCID mice, initiated by i.v. injection of 1.5 × 10 7 Daudi cells, a single 15 µg dose of hLL1-ranpirnase per animal, injected 1 day post tumor cell inoculation, led to 100% cure of animals (n = 7-8) for the duration of 150 days of the study, while untreated animals developed paralysis within 16-24 days. A single 1 µg dose of the immunotoxin significantly improved survival in comparison to untreated controls (P<0.0001).
Scope & Limitations
Some of the limitations of immunotoxin are in some ways similar to that for drug conjugates; namely, the need to treat every tumor cell and the problem of antigen heterogeneity. Antigen-negative cells lead to an immunotoxin-resistant population. One way to overcome this is to use agents that can stimulate a high-level expression of the antigen. One recent example is the demonstration of increased levels of CD38 antigen expression in vitro by using retinoic acid and of the synergistic combination of retinoic acid and anti-CD38 MAbgelonin immunotoxin in killing leukemia cells (112).
With bacterial and plant toxins, immunogenicity due to the toxin portion of the conjugate needs to be addressed, which does not appear to be a concern with RNases such as ranpirnase. PEGylation has been shown to minimize toxin-related immunogenicity of anti-Tac(Fv)-PE38 immunotoxin (113). Immunogenicity related to the antibody itself is readily addressed by using humanized or human MAbs or antibody fragments as part of the fusion proteins. Non-specific toxicity is another aspect to consider. Of these, the incidence of hepatotoxicity has been shown to be associated with carbohydrates on the toxin. The problem can be minimized by using a deglycosylated version of toxin, as has been demonstrated with deglycosylated ricin A-chain (96, 98). However, liver toxicity resulting from binding of toxin to non-carbohydrate receptors is not resolved by this method. In such instances, using anti-inflammatory agents and designing mutant versions of the toxin, with the removal of basic residues, have been suggested as approaches for ameliorating liver toxicity (98). With low molecular mass recombinant immunotoxins, renal toxicity is also of concern. Vascular leak syndrome is a serious toxicity often associated with ricin A-chain conjugates and also with conjugates of bacterial toxins. Again, mutating certain residues on the toxin proteins, to prevent binding to endothelium, has been suggested (98).
Conclusion
Targeted therapy using MAbs as carriers of radiation or chemotherapy drugs or toxins has come of age with the regulatory approvals of several such products for cancer treatment. Advances made thus far have expanded the choices of radionuclides and treatment protocols for radioimmunotherapy, emphasized the need for conditionally cleavable crosslinkers in drug conjugates, and facilitated recombinant and stable chemical conjugation techniques in the design of immunotoxins. The clinical potential of these therapies can be expected to be increasingly demonstrated in hematological malignancies. With respect to the more challenging solid tumors, two important observations have been made: First, multimodal combination therapies, applied judiciously, could prove to be more advantageous than single-agent therapies; and, second, RAIT in minimal-disease and adjuvant situations may be more useful than application in bulky tumors, and this may also prove to be true for drug-and toxin-MAb conjugates. Application as front-line therapies in newly diagnosed and untreated cancers, either alone or in combination with other modalities, also can be valuable. A caveat in all of these is how the new treatment paradigms would be allowed to be tested clinically, since most early studies are restricted to patients with advanced and bulky disease. It is to be hoped that continued scientific advances, business interests, and regulatory guidance could integrate for a greater impetus to the development of these targeted therapies. 
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